Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
STXS Stock Chart & Stats
$2.72
-$0.10(-4.18%)
At close: 4:00 PM EST
$2.72
-$0.10(-4.18%)
Day’s Range― - ―
52-Week Range$1.54 - $3.59
Previous CloseN/A
Volume282.58K
Average Volume (3M)524.71K
Market Cap
$247.71M
Enterprise Value$190.51M
Total Cash (Recent Filing)$10.51M
Total Debt (Recent Filing)$5.58M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Feb 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding91,071,480
10 Day Avg. Volume429,315
30 Day Avg. Volume524,706
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)16.99
Price to Sales (P/S)7.22
P/FCF Ratio-22.77
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue6.33
Enterprise Value/Gross Profit11.94
Enterprise Value/Ebitda-8.58
Forecast
1Y Price Target
$4.33Price Target Upside59.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company ended the quarter with $10.5 million in cash and no debt, indicating a strong financial position.
Product PerformanceRecurring revenue grew by 17%, driven by new sales of proprietary robotically navigated devices, indicating strong product performance.
Regulatory ApprovalsGenesisX's recent FDA clearance is viewed as a significant achievement, indicating potential growth for the company.
Bears Say
Revenue PerformanceQ3 revenue was below the Street estimate, highlighting a shortfall in expected performance.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.54 and its highest was $3.59 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $247.71M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Feb 27, 2026 which is in 102 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Nov 11, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.06 by -$0.01.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.06.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 91,071,480 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.06. Following the earnings report the stock price went down -14.737%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (59.19% Upside)
$4.33 (59.19% Upside)
Blogger Sentiment
Bullish
STXS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.82%
12-Months-Change
Fundamentals
Return on Equity
-170.24%
Trailing 12-Months
Asset Growth
14.32%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. is a leader in the field of robotic-assisted cardiac surgery and electrophysiology. Based in St. Louis, Missouri, the company develops advanced robotic systems and software for the treatment of complex heart conditions. Its flagship product, the Niobe® Robotic Magnetic Navigation System, enables the precise navigation of catheters in the heart, improving the accuracy and safety of procedures such as ablation for arrhythmias. Stereotaxis operates primarily in the medical technology sector and focuses on enhancing patient outcomes through innovation in cardiac care.
STXS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive trajectory for Stereotaxis with significant achievements like FDA approval for GenesisX and strong recurring revenue growth. However, financial losses and pending approvals are ongoing challenges.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$4.33
▲(59.19% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
21.70% Insiders
6.58% Mutual Funds
0.53% Other Institutional Investors
65.65% Public Companies and
Individual Investors